跳至主要内容
临床试验/NCT00760045
NCT00760045已完成2 期

Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time

Alcon Research1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2008年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
40
试验地点
1
主要终点
The change from baseline of non-invasive tear film break up time (ΔNIBUT: seconds).

研究概览

简要总结

The purpose of the study is to observe lacrimal fluid condition (tear film break-up time) chronologically after a single dose of AL-43546 ophthalmic products(0.15%, 0.25% and vehicle)and 0.1% sodium hyaluronate ophthalmic solution and compare lacrimal fluid retention time between them.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 64 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects with NIBUT of either eye is 8 seconds or less and other eye is 10 seconds or less at screening test and NIBUT of either eye before instillation in Period I is 10 seconds or less.

排除标准

  • Diagnosis of severe Sjogren's syndrome (history of the use of punctal plug one time or more, etc.) in either eye.
  • Subjects who will use ophthalmic solutions (excluding the specified artificial tear) or ophthalmic ointment in either eye during the study period.

研究组 & 干预措施

1

Experimental

AL-43546 0.15%

干预措施: Hydroxypropyl Guar Galactomannan (Drug)

2

Experimental

AL-43546 0.25%

干预措施: Hydroxypropyl Guar Galactomannan (Drug)

3

Active Comparator

AL-43546 0%(Vehicle)

干预措施: Hydroxypropyl Guar Galactomannan (Drug)

4

Active Comparator

0.1% sodium hyaluronate ophthalmic solutio

干预措施: 0.1% sodium hyaluronate ophthalmic solution (Drug)

结局指标

主要结局

The change from baseline of non-invasive tear film break up time (ΔNIBUT: seconds).

时间窗: Up to 180 minutes

次要结局

  • Ocular comfort(After installation)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验